Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
PRO-1184 by ProfoundBio Suzhou for Peritoneal Cancer: Likelihood of Approval
PRO-1184 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Peritoneal Cancer. According to GlobalData, Phase...
Data Insights
PRO-1184 by ProfoundBio Suzhou for Fallopian Tube Cancer: Likelihood of Approval
PRO-1184 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Fallopian Tube Cancer. According to GlobalData,...